Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or
mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal
failure, who presented for a kidney-pancreas transplant.